+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
CONCORD

Concord Drugs Share Price

 

 

Concord Drugs live price: ₹76.9.

Concord Drugs Performance

  • Today's Low
  • ₹0
  • Today's High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume
  • 50 DMA₹79.05
  • 100 DMA₹78.35
  • 200 DMA₹73.48

Concord Drugs Chart

Investment Returns

  • Over 1 Month -6.66%
  • Over 3 Month + 9.37%
  • Over 6 Month -7.47%
  • Over 1 Year + 123.09%

Smart Investing Starts Here Start SIP with Concord Drugs for Steady Growth!

Invest Now

Concord Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Concord Drugs Financials

Concord Drugs Technicals

EMA & SMA

Current Price
₹76.90
-0.05 (-0.06%)
  • Bearish Moving Average 0
  • Bullish Moving Average 0
  • 20 Day
  • ₹78.00
  • 50 Day
  • ₹79.00
  • 100 Day
  • ₹78.40
  • 200 Day
  • ₹73.50

Resistance and Support

75.35 Pivot Speed
  • R3 85.99
  • R2 82.35
  • R1 78.99
  • S1 71.99
  • S2 68.35
  • S3 64.99

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Concord Biotech Limited is an R&D-driven biopharma company with two API units and one formulation unit in Gujarat, India. The company supplies APIs and finished formulations across 70+ countries, including the USA, Europe, Japan, and India.

Concord Biotech Ltd has an operating revenue of Rs. 1,054.89 Cr. on a trailing 12-month basis. An annual revenue de-growth of -11% needs improvement, Pre-tax margin of 32% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and around 9% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 46 which is a POOR score indicating inconsistency in earnings, a RS Rating of 41 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 31 indicates it belongs to a strong industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Concord Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-27 Audited Results
2026-02-14 Quarterly Results
2025-11-13 Quarterly Results
2025-08-08 Quarterly Results
2025-07-03 Preferential issue of shares

Concord Drugs Shareholding Pattern

44.08%
4.3%
3.89%
7.79%
0%
8.09%
31.85%

Concord Drugs FAQs

Concord Drugs share price is ₹76 As on 30 June, 2026 | 21:31

The Market Cap of Concord Drugs is ₹101.3 Cr As on 30 June, 2026 | 21:31

The P/E ratio of Concord Drugs is 96 As on 30 June, 2026 | 21:31

The PB ratio of Concord Drugs is 2.1 As on 30 June, 2026 | 21:31

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23